Close Menu

This article has been updated to correct an error about the FDA's alert regarding three SARS-CoV-2 molecular tests.

NEW YORK – Thermo Fisher Scientific said on Tuesday that it plans to acquire point-of-care molecular diagnostics firm Mesa Biotech for up to $550 million.

Under the terms of a definitive agreement, Thermo Fisher will pay approximately $450 million in cash and up to an additional $100 million in cash if certain milestones are met after the acquisition.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.